Sucampo Pharmaceuticals
| Industry | Pharmaceutical industry |
|---|---|
| Founded | 1996 |
| Defunct | February 12, 2018 |
| Fate | Acquired by Mallinckrodt |
| Headquarters | Rockville, Maryland |
Key people | Peter Greenleaf (CEO and (Chairman) Andrew P. Smith (CFO) |
| Products | Amitiza |
| Revenue | $230 million (2016) |
| $18 million (2016) | |
| Total assets | $520 million (2016) |
| Total equity | $167 million (2016) |
Number of employees | 139 (2017) |
| Website | www |
| Footnotes / references | |
Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. In 2018, the company was acquired by Mallinckrodt.
Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma. Takeda Pharmaceutical Company had a license to distribute Rescula globally except for in Japan and China. The company had two Phase III drugs in development for rare diseases — one for Niemann-Pick Type C and the other for familial adenomatous polyposis, which can cause colon cancer if untreated.